Arcus Biosciences (RCUS) Q3 2026 earnings review
Arcus kidney cancer data impresses, while a stock sale funds trials
Arcus Biosciences, a clinical-stage cancer drug developer, backed up its main kidney cancer pill with October trial data and used the moment to raise cash. Third-quarter revenue dropped 65% to $9 million as its partnership with Gilead Sciences wound down, while research spending fell 17% after the company closed older failed studies. Chief executive Terry Rosen highlighted nearly three years of median survival in late-stage kidney cancer patients, and an October stock sale added $288 million to extend funding into 2029.
| Collaboration revenue | $9M -65% from a year ago |
|---|---|
| Research and development expense | $117M -17% from a year ago |
| Cash plus October stock sale (by our math) | $982M funds operations into 2029 |
| Full-year revenue outlook | Raised $2.5M middle of the range: $72.5M |
⚖️ Verdict: 🟢 Bullish
The story got better because the October clinical data and the stock sale answered two immediate risks: early three-drug safety cleared the way to start the first-line Phase 3 trial by year-end, and the cash raise removed funding pressure until 2029. One caution: the company changed its research spending plan from declining to staying flat as partner cost-sharing dried up, and enrollment completion for its second-line Phase 3 trial slipped into early 2027.
The question now is whether Arcus's kidney cancer pill can repeat its single-arm results in head-to-head Phase 3 trials without driving quarterly cash burn back up. Either the self-funded Phase 3 studies validate the drug while costs stay near $117 million a quarter, or trial delays and lost partner reimbursements force another round of shareholder dilution. Finishing PEAK-1 enrollment in the next two to three months and fourth-quarter research spending will give the next reading.
🐂 Bull Case
October Data Strengthened the Case for Casdatifan
Arcus is betting its future on casdatifan, an experimental pill that blocks a protein called HIF-2 alpha to starve kidney tumors. Chief executive Terry Rosen said the company is "building the registrational evidence to make casdatifan the backbone of treatment across the continuum of care for clear cell renal cell carcinoma". In October, the drugmaker released data from its ARC-20 trial testing the pill across three stages of kidney cancer.
- Late-line patients on casdatifan alone: median overall survival of 35 months across 121 patients
- Second-line patients on casdatifan plus cabozantinib: median progression-free survival (time before cancer worsens) of 14.5 months, and 16.5 months for patients whose prior tyrosine kinase inhibitor (TKI, a standard cancer pill) stopped working
- First-line patients on casdatifan plus zimberelimab (an immune therapy): 69% lived without cancer worsening at 12 months
- First-line three-drug combination: only 1 of 24 scanned patients had their cancer worsen immediately, with no unexpected safety issues
These results matter because they address two standing concerns. First, the 16.5-month reading in patients who already took a standard TKI pill supports using the drug in the 60% of second-line patients who need a new option. Second, clean early safety in the three-drug group lets the biotech start its Phase 3 PEAK-20 trial before year-end.
What to watch: the start of the Phase 3 PEAK-20 trial in the fourth quarter of 2026. Activating the trial on schedule will confirm that regulators accepted the three-drug safety data.
An October Stock Sale Extended Cash Into 2029
A central risk for Arcus has been funding an expanding slate of large Phase 3 trials from a shrinking cash pile while issuing new shares. During the third quarter, cash and marketable securities fell by $81 million to $694 million. By our math, that quarterly cash use beat the $88 million pace implied by the prior year-end cash plan.
In October, the company raised $288 million in gross proceeds by selling stock after presenting its kidney cancer data. Arcus said its $694 million balance "together with $288 million gross proceeds from its October equity financing will be sufficient to fund its planned level of operations into 2029". That extends the cash plan from the second half of 2028 and removes near-term funding pressure, though it adds to a share count that had already risen 19.6% from a year ago.
What to watch: the year-end 2026 cash balance and share count in the annual report. Those figures will show the net cash kept from the October stock sale and how much dilution existing shareholders took.
Partner Trials and the Immunology Pipeline Stay on Track
To broaden casdatifan without paying for every study alone, Arcus teamed up with other drugmakers and built an internal pipeline of pills for immune diseases. Three first-line kidney cancer cohorts pairing casdatifan with bispecific antibodies (drugs that bind two targets at once) from Summit Therapeutics, Bristol Myers Squibb and Pfizer remain on track to start before year-end.
Outside kidney cancer, the company conducted an August healthy-volunteer study for AB102, an oral pill for inflammatory skin conditions, hitting its third-quarter target. It also scheduled a fourth-quarter interim analysis for PRISM-1, a fully enrolled Phase 3 trial of quemliclustat (a small-molecule cancer drug) in pancreatic cancer. These steps show the drugmaker can run early immune studies and partner trials alongside its main kidney cancer push.
What to watch: any disclosure from the fourth-quarter PRISM-1 interim analysis in pancreatic cancer. A positive safety or efficacy update would give the company a second late-stage asset beside casdatifan.
🐻 Bear Case
Every Efficacy Claim Still Relies on Outside Studies
Rosen highlighted "nearly three years of median overall survival in late-line patients who had exhausted multiple therapies" and said second-line results beat standard benchmarks. However, ARC-20 is a single-arm study in these groups, meaning patients all took the experimental regimen rather than competing directly against a control group in the same trial.
A footnote in the release states that "all referenced benchmarks are based on third-party data and do not represent head-to-head comparisons between casdatifan and any other products or candidates". Meanwhile, completion of enrollment in PEAK-1, the randomized Phase 3 second-line trial designed to prove the drug beats cabozantinib head-to-head, moved from year-end 2026 to "the next two to three months". A new cohort combining casdatifan with axitinib also shifted from the fourth quarter to the first half of 2027.
What to watch: completion of PEAK-1 enrollment in early 2027. Any further delay in finishing enrollment would push back the first randomized Phase 3 readout that can validate the ARC-20 comparisons.
Research Spending Stopped Falling as Gilead Stepped Back
After shutting down three failed Phase 3 trials of its older drug domvanalimab with partner Gilead Sciences, Arcus had told investors that research and development (R&D) spending would keep declining. In the third quarter, R&D expenses fell 17.0% from a year ago to $117 million, but rose from $113 million in the second quarter.
Because revenue dropped 65.4% from a year ago to $9 million as the Gilead partnership wound down, R&D jumped by 758 percentage points of revenue. Gross expense reimbursements from partners fell from $28 million a year ago to $12 million as Arcus shifted to self-funded trials. The company now expects R&D spending to "remain relatively consistent in the near term" rather than fall further, because new casdatifan and immunology trials offset the domvanalimab savings.
What to watch: fourth-quarter R&D expenses and partner reimbursements. Rising trial costs as PEAK-20 starts would test whether the company can keep quarterly spending near $117 million.
Risks this quarter didn't answer
Several standing financial and clinical watch items were not disclosed in the third-quarter earnings release and await the quarterly filing or future updates.
- Deferred revenue balance: not in the release; the quarterly filing's revenue footnote will show how much of the $56 million June balance remains and where the expected $15 million Taiho payment landed.
- R&D spending by drug: not in the release; the quarterly filing's expense table will show whether closed domvanalimab trials have stopped driving late-stage costs.
- Exact prior-drug breakdown in second-line kidney cancer: the release gave median progression-free survival for TKI-pretreated patients, but did not break out how many took lenvatinib specifically.
💲 Other KPIs
Overhead and administrative spending fell 14.8% from $27 million a year ago and edged down from $24 million in the second quarter. Arcus attributed the drop to streamlining steps across its operations. Non-cash stock-based compensation within this line stayed at $7 million, unchanged from a year ago.
The quarterly net loss narrowed 5.2% from $135 million a year ago, when research spending was higher, but widened from $91 million in the second quarter. Last quarter's loss was smaller because the drugmaker recorded a one-time revenue boost when Gilead ended its pipeline continuation rights. Net loss per share was $1.00, down from $1.27 a year ago.
The average share count rose 19.6% from 106.5 million a year ago and ticked up from 126.1 million in the second quarter. That increase reflects stock offerings completed in 2025 to fund clinical trials. Because the third quarter ended in September, this figure does not yet include the shares sold in the $288 million October financing.
🔮 Guidance
Raised. Arcus lifted the bottom of its full-year revenue outlook by $5 million, putting the middle of the range at $72.5 million. That is a 70.6% drop from last year's $247 million (or down 30.3% by our math excluding last year's $143 million accounting catch-up). With $67 million booked in the first nine months, by our math the plan leaves $3 million to $8 million for the fourth quarter. Third raise this year: +$7.5M, +$12.5M, +$2.5M.
Raised. Management now expects research and development costs to stay flat in the near term near the third quarter's $117 million level, whereas its prior outlook called for spending to keep falling. The shift happens because rising costs for Phase 3 casdatifan trials and early immune pills now match the savings from shutting down the older domvanalimab studies.
Raised. The biotech extended its expected funding horizon from the second half of 2028 into 2029. The longer timeline rests on the $694 million third-quarter cash balance plus $288 million in gross proceeds raised from an October stock offering, which together total $982 million by our math before offering fees.
❓ Key Questions
Where did the $15 million Taiho milestone payment go?
Last quarter's filing notes pointed to a $15 million milestone payment from Taiho Pharmaceutical in the third quarter for Japanese trial enrollment. Total third-quarter revenue was only $9 million, so investors need to know if the payment was delayed or booked in deferred revenue.
Why did PEAK-1 enrollment and the axitinib cohort slip?
Arcus previously planned to finish enrolling its Phase 3 PEAK-1 trial and start its casdatifan-plus-axitinib cohort by year-end 2026. Both moved into the first half of 2027, raising the question of whether site activation or patient screening slowed down.
How much will R&D rise once PEAK-20 starts enrolling?
The company now says R&D spending has stopped falling at $117 million per quarter as partner reimbursements shrink. With the large Phase 3 PEAK-20 study starting by year-end, management has not said whether quarterly cash burn will climb back above $100 million in 2027.
How manyshares were issued in the October financing?
The release disclosed $288 million in gross proceeds from the October equity offering but gave no share count or net proceeds. That number determines how much ownership dilution shareholders took to extend the cash runway into 2029.